Cargando…

Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer’s Disease

Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive decline, little is known about their underlying molecular mechanisms and relationships with Alzheimer’s disease (AD). The aim of this study was to identify and characterize cerebrospinal fluid (CSF) p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mroczek, Magdalena, Clark, Christopher, Dayon, Loïc, Bowman, Gene L., Popp, Julius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947516/ https://www.ncbi.nlm.nih.gov/pubmed/35326481 http://dx.doi.org/10.3390/cells11061030

Ejemplares similares

Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people
por: Clark, Christopher, et al.
Publicado: (2022)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Persisting neuropsychiatric symptoms, Alzheimer’s disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate
por: Ouanes, Sami, et al.
Publicado: (2022)

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease
por: Clark, Christopher, et al.
Publicado: (2021)

The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer’s disease
por: Clark, Christopher, et al.
Publicado: (2022)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Exploration of human cerebrospinal fluid: A large proteome dataset revealed by trapped ion mobility time-of-flight mass spectrometry
por: Macron, Charlotte, et al.
Publicado: (2020)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Autoantibody Profiling on Human Proteome Microarray for Biomarker Discovery in Cerebrospinal Fluid and Sera of Neuropsychiatric Lupus
por: Hu, Chaojun, et al.
Publicado: (2015)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Weight Change and Neuropsychiatric Symptoms in Alzheimer’s Disease and Frontotemporal Dementia: Associations with Cognitive Decline
por: Morrow, Christopher B., et al.
Publicado: (2023)

Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance
por: Tautvydaitė, Domilė, et al.
Publicado: (2017)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)

Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline
por: Pink, Anna, et al.
Publicado: (2023)

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
por: Wildsmith, Kristin R, et al.
Publicado: (2014)

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
por: Johnson, Erik C. B., et al.
Publicado: (2023)

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
por: Cruchaga, Carlos, et al.
Publicado: (2010)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Quantitative proteomics of delirium cerebrospinal fluid
por: Poljak, A, et al.
Publicado: (2014)

Identification of Novel Cerebrospinal Fluid Biomarkers for Cognitive Decline in Aneurysmal Subarachnoid Hemorrhage: A Proteomic Approach
por: Liu, Fan, et al.
Publicado: (2022)

Identification of Candidate Biomarkers of Alzheimer’s Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics
por: Liu, Ping, et al.
Publicado: (2023)

Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
por: Dammer, Eric B., et al.
Publicado: (2023)

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease
por: De Vos, Ann, et al.
Publicado: (2016)

Low Cerebrospinal Fluid Levels of Hemopexin Are Associated With Increased Alzheimer's Pathology, Hippocampal Hypometabolism, and Cognitive Decline
por: Ashraf, Azhaar A., et al.
Publicado: (2020)

Rubidium and potassium levels are altered in Alzheimer’s disease brain and blood but not in cerebrospinal fluid
por: Roberts, Blaine R., et al.
Publicado: (2016)

Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer’s Disease
por: Park, Jung Hyun, et al.
Publicado: (2022)

Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Lopez-Font, Inmaculada, et al.
Publicado: (2022)

One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond
por: Dayon, Loïc, et al.
Publicado: (2017)

Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A Systematic Review
por: Mroczek, Magdalena, et al.
Publicado: (2022)

Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
por: Nowrangi, Milap A, et al.
Publicado: (2015)

Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
por: Iravani, Behnam, et al.
Publicado: (2022)

Network Analysis of Neuropsychiatric Symptoms in Alzheimer’s Disease
por: Goodwin, Grace J., et al.
Publicado: (2023)

Network analysis of neuropsychiatric symptoms in Alzheimer’s disease
por: Goodwin, Grace J., et al.
Publicado: (2023)

Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19
por: Ngo, Binh, et al.
Publicado: (2021)

Cerebrospinal fluid exosomal protein alterations via proteomic analysis of NSCLC with leptomeningeal carcinomatosis
por: Hou, Lan, et al.
Publicado: (2023)

Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis
por: Fragoso-Loyo, Hilda, et al.
Publicado: (2008)

Establishing the Proteome of Normal Human Cerebrospinal Fluid
por: Schutzer, Steven E., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_v5ncrpksnkdbad99npiqp700cm